• PDF / 146,599 Bytes
• 1 Pages / 623.591 x 841.847 pts Page_size
• 28 Downloads / 216 Views

DOWNLOAD

REPORT

IGT

Orlistat

Placebo

Orlistat

7.968

7.891

7.921

6.641 15.29 60.8

6.26 16.02 -

6.396 18.17 16.34

Quality-adjusted life expectancy Incremental cost-utility ratio

The researchers concluded that "orlistat shows a good pharmacoeconomic profile, especially in IGT patients, with a cost-utility of 16.340 Euro/QALY. This values is lower than that of several therapeutic strategies commonly accepted in developed countries." * This study was sponsored by Roche Spa, Milan, Italy, and presented at the 10th Annual European Congress of the International Society of Pharmacoeconomic and Outcomes Research. Iannazzo S, et al. A probabilistic Bayesian Markov model in WinBUGS for the economic evaluation of the treatment with orlistat of Italian obese patients. Value in Health 10: A462-A463 (plus poster) abstr. POB3, No. 6, Nov-Dec 801084960 2007

1173-5503/10/0541-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved

PharmacoEconomics & Outcomes News 17 Nov 2007 No. 541

1

Recommend Documents

Further hearing screens may be required for infants

162 23 59KB

Direct-to-consumer ads may be beneficial for aromatase inhibitors

186 6 140KB

Monitoring abiraterone levels may be cost effective

171 22 184KB

Catch-22 for regulators: risk aversion may be harmful

167 7 111KB

High doses of diphenhydramine may be fatal

153 79 147KB

ISIC17 to be held in Japan in May 2013

165 94 204KB

Nonoperative management of inflamed gallbladder may be best for elderly

168 109 79KB

Dislocation pileups in microcantilevers may be fully reversible

171 52 179KB

Health Care Systems Engineering HCSE, Florence, Italy, May 2017

161 27 6MB

Patients may be safely vaccinated even after allergic reactions

166 97 139KB

Nonfunctional adrenal incidentalomas may be related to bisphenol-A

149 63 433KB

Energy Focus: Charge-density waves may be competing with superconductivity

190 61 257KB